[Value of delta model for end-stage liver disease in evaluating the prognosis of liver failure patients with hepatitis B virus].
OBJECTIVE
To evaluate the prognostic value of the model for end-stage liver disease (MELD) and deltaMELD in liver failure patients infected with hepatitis B virus.


METHODS
Based on prospective study design, 98 hospitalized cases were studied and followed up for 24 weeks. The clinical data were recorded. We calculated the score of MELD and deltaMELD, and also compare the score between the survival group and death group. Using ROC curve plotting obtained the better decisive threshold. The case fatality rate were compared at different time points which the patients were classified by the best critical value of MELD and deltaMELD. We draw the Kaplan-Meier survival curve of different group and analyse the change of survival rate by log-rank analysis.


RESULTS
52 of 97 patients died and 46 survive during 24 weeks of followup. There was significant difference between the two groups for MELD and deltaMELD (P < 0.01). The case fatality rate in group which MELD > or = 23 was obviously higher than in that MELD < 23. The rate in group which deltaMELD > 4.5 was obviously higher than in that deltaMELD < 4.5 (P < 0.001). The area under curve (AUC) for the twelfth and 24th week's prognosis judgment of deltaMELD (0.823, 0.815) was larger than that of MELD (0.680, 0.684) (P < 0.05). Survival analyses (Kaplan-Meier) indicated that there were significant differences in cumulative survival rates among the groups which were grouped by optimization critical value ( P = 0. 000).


CONCLUSIONS
The scoring system of MELD also applied to the forecasting of prognosis for severe hepatitis B patients in China. The accuracy of deltaMELD to predict the prognosis was higher than that of MELD. The combination of MELD and deltaMELD showed good clinical practical value.
Dept. of Integrated TCM and Western Medicine, Hangzhou No. 6 People' Hospital, Zhejiang 310014, China. guojianchun1961@126.com
Jian-Chun
JC
Guo
Chun-Qing
CQ
Li
Yun-Hao
YH
Xun
Yu-Fang
YF
Wang
Xiu-Li
XL
Yu
Wei-Zhen
WZ
Shi
Jun-Ping
JP
Shi
Cuo-Qiang
CQ
Lou
D058625:End Stage Liver Disease / Q000175:diagnosis*; D006509:Hepatitis B / Q000150:complications*; D006801:Humans; D053208:Kaplan-Meier Estimate; D017093:Liver Failure / Q000209:etiology / Q000401:mortality*; D008954:Models, Biological; D011379:Prognosis; D012372:ROC Curve; D012720:Severity of Illness Index